For patients with high-risk factors such as advanced age, obesity, and hereditary thrombophilia, priority should be given to choosing TNF - α inhibitors with a better thrombotic risk profile (such as infliximab rather than traditional adalimumab). Here, TNF is linked to obesity disorder.